When: 50/200 SMA pullback to $85-87

Then: Entry for remaining 50% of intended new capital size

When: Confirmed close above $98 on volume >10M with MACD positive re-cross

Then: Entry for remaining 50% of intended new capital size

HOLD for existing holders with stops at $88.50; do not deploy new capital at $92.77—wait for $85-87 pullback or breakout confirmation above $98-100

• Three failed attempts at $94 with MACD bearish crossover indicates distribution, not accumulation—price hugging $94 means sellers are actively engaged
• Forward P/E of 14.5x against $6.41 EPS already prices in optimistic scenario; trailing P/E of 22.85x at $4.06 EPS shows market is paying for growth that requires no setbacks
• 58% earnings jump requires everything to go right: no FX headwinds, no MiniMed integration hiccups, no tariff disruption, no hospital capital spending slowdown
• MiniMed separation is a multi-quarter process creating $72-142 million per quarter in restructuring charges, headline risk, and valuation uncertainty—not a clean day-one catalyst
• MDT being flat while BSX drops 57% is stagnation, not momentum; likely held by income-oriented investors creating artificial floor
• 95% probability of no rate cuts in 2026 keeps discount rate elevated, capping forward multiples rather than expanding them
• Aggressive entry at $92-77 with 75% allocation means paying 7-8% premium over $85-87 zone with identical stop parameters—inefficient capital deployment
• With 0.57 beta, stock offers low volatility and ample time to wait for better entry; rushing low-beta names contradicts their nature
• 3.1% dividend at $92.77 generates ~$2.88/share annually—does not hedge downside, only softens 8.3% paper loss if stock drops to $85
• At 4-5% treasury rates, locking capital in equity for $2.88 yield is inferior to $4+ in money market with zero equity risk
• Goodwill and intangibles of $53.4 billion represent 57% of total assets; tangible book value is negative at -$3.19 billion
• 10% goodwill impairment on existing base would equal $5+ billion charge—meaningful risk if acquisitions underperform during MiniMed separation
• Staged 50/50 approach (half at $85-87, half on breakout confirmation) is correct risk management for defensive name

→ vs aggressive: Claims three failed attempts at $94 represent quiet accumulation; actually textbook distribution with sellers actively engaged at supply line

→ vs aggressive: Forward P/E of 14.5x already prices in bull case—trailing P/E of 22.85x reveals what market paid historically; any miss on $6.41 EPS causes multiple compression, not expansion

→ vs aggressive: MiniMed separation is multi-quarter disruption with $72-142M quarterly charges, not clean catalyst for day-one re-rating

→ vs aggressive: Relative strength argument (MDT flat vs BSX -57%) is stagnation story with yield wrapper, not momentum story

→ vs aggressive: 95% no-rate-cuts probability caps multiples, doesn't expand them; hawkish Fed is headwind for equity valuations, not tailwind

→ vs aggressive: 75/25 split at $92-93 is 7-8% premium entry with identical stop parameters—inefficient capital deployment vs waiting for $85-87

→ vs aggressive: Dividend yield of 3.11% is not free option to wait—at 4-5% treasuries, money market earns more with zero equity risk

→ vs aggressive: Goodwill risk of $53.4B (57% of assets) with negative tangible book value completely ignored in bull thesis

→ vs neutral: $90-90.80 entry zone too high; $88.50 stop too tight given 50/200 SMA cluster at $88.37-88.50—push stop to $87.50-87.80 to avoid routine wick-outs

→ vs neutral: Lower Bollinger Band at $90.02 is not aggressive enough entry; wait for test of $89.50 or $89.00 with volume confirmation

HOLD with refined 50/50 staged entry plan; commit only 50% of intended new capital to the staged approach, holding remaining 50% in cash reserves

• Aggressive analyst's fundamental case is strong (41% EPS growth over five quarters, $5.94 guidance, Hugo LigaSure clearance, 3.1% dividend yield) but entry execution is critically flawed
• R/R calculation at current entry ($92.77) to $100 target is 1.7:1, not the claimed 2:1, with $4.27 per share downside risk on 75% deployed tranche
• MACD histogram negative, MACD line below signal, RSI at 56 unable to break through 70 on three $94 tests indicates resistance, not quiet accumulation
• Conservative analyst correct that paying full price at supply zone is bad risk management, but overstates goodwill/negative tangible book as primary avoidance reason—it is a watch item, not a disqualifier
• MDT holding flat while peers collapse constitutes relative strength in a de-rating sector; captive yield-driven bid underneath provides structural floor
• Base case R/R into $94 resistance vs $88 support is roughly 1:1, confirming trader's original assessment
• Proposed refinements: Stop at $87.50-$87.80 (between aggressive's $88.50 and conservative's $88.40); first tranche at $89-$90 on declining volume test of lower Bollinger band; 50% of new capital to staged plan, 50% held in cash

→ vs aggressive: R/R calculation overstated—actual ratio is 1.7:1 not 2:1; asking to take real loss now for probable move requiring market to reward bull case materially is not asymmetric

→ vs aggressive: Three failures at $94 represent resistance, not accumulation—MACD negative, MACD below signal, RSI at 56 unable to push through 70 indicates buyers running out of oxygen

→ vs conservative: MDT standing flat while peers collapse IS relative strength in a de-rating sector—not the same as absolute momentum but institutional bid is present and structural floor is real

→ vs conservative: Goodwill concern is legitimate watch item but not primary avoidance reason; elevated goodwill is legacy of decades of M&A, not sudden balance sheet risk

→ vs conservative: Both hawkish Fed effects can be true simultaneously—elevated rates cap multiple expansion AND defensives with yield get bid; MDT should hold current valuation rather than re-rate dramatically